stockrow
Saturday 7 November 2026
Export STLN’s income statement to Excel — free account
Starling Oncology, Inc.
STLN Healthcare Medical Care Facilities
Starling Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.7 million, up 27.8% from fiscal 2024.
- Revenue
- +24.3%
- EPS
- +7.14%
- Free cash flow
- +167.1%
- Total debt
- −4.82%
Quarter to September 2026, against a year earlier
3.51
3.19
−47.61%
Follow STLN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 6 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.65 | 0.57 | 0.95 | 1.07 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 35.15 | |
P/Operating CF |
101.73 | (141.10) | 46.86 | 65.26 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.74 | 0.66 | 1.02 | 1.12 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(15.17) | (16.55) | 1,824.43 | 30.20 | |
EV/FCF |
(13.42) | (14.03) | (182.11) | 37.06 | |
Quick Ratio |
1.31 | 1.13 | 1.14 | 0.79 | |
Current Ratio |
1.59 | 1.47 | 1.36 | 1.11 | |
Net Debt/EBITDA |
(10.77) | (13.11) | (25.47) | 0.00 | |
Debt/Assets |
47.01% | 46.73% | 44.81% | 38.62% | |
Debt/Equity |
(4.92) | (4.83) | (3.21) | (1.94) | |
Asset Turnover |
2.98 | 3.29 | 3.47 | 3.53 | |
Operating CF/Net income |
(0.43) | 0.89 | (1.22) | (0.64) | |
Capex/Depreciation |
(0.37) | (0.37) | (0.29) | 0.00 | |
Interest Coverage |
(3.60) | (3.37) | (2.48) | (1.64) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
19.75% | 19.13% | 18.57% | 18.93% | |
Intangible Assets out of Total Assets |
0.11 | 0.10 | 0.09 | 0.09 | |
Share Based Compensation of Revenue |
0.93% | 1.14% | 0.66% | 0.79% | |
Graham Net Nets |
(0.21) | (0.22) | (0.13) | (0.13) | |
Graham Number |
1.46 | 1.15 | 1.28 | 1.53 | |
Earnings Yield |
(15.73%) | (12.05%) | (5.52%) | (4.59%) | |
Free Cash Flow Yield |
(8.45%) | (8.23%) | (0.59%) | 2.84% | |
Revenue per Share |
1.54 | 1.45 | 1.57 | 1.62 | |
Operating CF per Share |
0.04 | (0.02) | 0.12 | 0.10 | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Free Cash Flow per Share |
0.02 | (0.03) | 0.11 | 0.08 | |
Cash per Share |
0.36 | 0.30 | 0.40 | 0.35 | |
Shareholders Equity per Share |
(0.17) | (0.16) | (0.24) | (0.36) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.17) | (0.16) | (0.24) | (0.36) | |
Free Cash Flow |
2.17 | (3.26) | 11.03 | 8.88 | |
Working Capital |
41.79 | 37.51 | 34.05 | 13.99 | |
Capital Expenditures |
(1.06) | (1.04) | (0.91) | (1.26) | |
Net Current Asset Value |
(67.63) | (67.65) | (74.16) | (87.44) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
54.00 | 54.56 | 61.32 | 60.39 | |
Average Payables |
33.75 | 38.47 | 47.61 | 58.86 | |
Average Inventory |
13.46 | 18.30 | 17.90 | 27.76 | |
Average Assets |
168.69 | 166.12 | 169.02 | 175.70 | |
Average Common Equity |
(6.07) | (5.61) | (16.95) | (24.81) |
Columns are period end dates · fundamentals updated 6 Nov 2026